ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Researchers Find Two Types Of MCL Drug Resistance

August 29, 2014

Panel To Take Up Issues In Grant/Peer Review System, Consider NCAB Membership Requirements

December 11, 1981

Some NCAB Members Lack Understanding f Bypass Budget’s Value, Purpose

September 1, 1989

Duke Insiders Allege Intimidation By Administration

July 23, 2010

ASCO Weighs In On Tobacco Debate

September 19, 1997

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007